ACET ADICET BIO INC US FDA Inspections 8-K Filing 2024 - FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma Adicet Bio announces FDA clearance of IND application for ADI-270 in Renal Cell Carcinoma and plans to initiate a Phase 1 clinical trial.Get access to all SEC 8-K filings of the ADICET BIO INC